With its cam­pus ex­pand­ing as gene ther­a­py booms, Alde­vron brings in a top ex­ec from a medtech gi­ant to steer the course

We now know where Kevin Ballinger was head­ed when he un­ex­pect­ed­ly hand­ed in his res­ig­na­tion ear­li­er this month as one of the top EVPs at medtech gi­ant Boston Sci­en­tif­ic, where he’s spent the last 25 years.

Ballinger is land­ing in Far­go, ND, where he’s now tak­ing the reins as the new CEO at Alde­vron, one of the world’s top man­u­fac­tur­ers of plas­mid DNA, mR­NA, CRISPR/Cas9, vec­tors and more, serv­ing the bur­geon­ing world of gene ther­a­py de­vel­op­ers around the world.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN